Our business strategy is to do what we do best — develop our ZFP technology through research, preclinical and early stage clinical testing. We then look for partners to help us fully realize the value of certain programs through late stage clinical trials and commercialization.
Our plan is to partner certain programs at points of value inflection. In early 2014 we established a collaboration with Biogen to develop a ZFP Therapeutic approach for beta-thalassemia and sickle cell disease. In early 2012 we established a partnership with Shire AG to develop ZFP Therapeutics for hemophilia, Huntington's disease and other monogenic diseases.
To contact our Business Development team, please email: email@example.com